📇 Rhumatologue · PARIS CEDEX 04 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE HOTEL DIEU
1 PL DU PARVIS DE NOTRE DAME, 75181 PARIS CEDEX 04
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of pain and symptom management · 2014
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
Purpose To investigate the somatostatin analog lanreotide as symptomatic treatment for inoperable bowel obstruction due to peritoneal carcinomatosis. Patients and Methods In all, 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstruction, and two or more vomiting episodes per day or nasogastric tube (NGT) who were previously treated with intravenous corticosteroids and proton pump inhibitors were randomly assigned to one 30-mg injection of lanreotide microparticles (n = 43) or placebo (n = 37) in a 10-day, double-blind, parallel-group phase. The primary end point was the proportion of patients responding on day 7 (one or fewer episodes of vomiting per day or no vomiting recurrence after NGT removal [for ≥ 3 consecutive days in both cases]). Vomiting frequency/NGT secretion volumes, nausea, abdominal pain, well-being, and safety were also assessed. Patients could then enter an open-label lanreotide-only phase. The study was conducted at 22 European hospitals. Results More patients receiving lanreotide than placebo were responders; this difference was not statistically significant for the intent-to-treat (ITT) population on the basis of diary cards (primary analysis; 41.9% [18 of 43] v 29.7% [11 of 37], respectively; odds ratio, 1.75; 95% CI, 0.68 to 4.49; P = .24) but was statistically significant for the corresponding supportive per protocol analysis (57.7% [15 of 26] v 30.4% [seven of 23]; P < .05) and ITT analysis, on the basis of investigators' assessments (50.0% [19 of 38] v 28.6% [10 of 35]; P < .05). Improvements in well-being were significantly greater with lanreotide on days 3, 6, and 7. No significant differences were observed for other secondary end points. Only two (mild/moderate) treatment-emergent adverse events were considered related to lanreotide. Conclusion These results show that lanreotide has some efficacy and is safe in the symptomatic treatment of patients with inoperable bowel obstruction due to peritoneal carcinomatosis.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Investigational new drugs · 2015 · Case Reports
Combe P, Chauvenet L, Lefrère-Belda MA, Blons H, et al.
Journal of pain and symptom management · 2014 · Journal Article
Laval G, Marcelin-Benazech B, Guirimand F, Chauvenet L, et al.
Gynecologic oncology · 2013 · Journal Article
Emile G, Chauvenet L, Tigaud JM, Chidiac J, et al.
Journal of geriatric oncology · 2013 · Clinical Trial, Phase II
Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · Clinical Trial, Phase III
Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, et al.
PloS one · 2017 · Journal Article
Laroche F, Perrot S, Medkour T, Cottu PH, et al.
Journal of geriatric oncology · 2013 · Clinical Trial, Phase II
Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, et al.
PloS one · 2017 · Journal Article
Laroche F, Perrot S, Medkour T, Cottu PH, et al.